Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

26.15
+0.81003.20%
Post-market: 26.150.00000.00%19:03 EDT
Volume:80.81K
Turnover:2.11M
Market Cap:1.70B
PE:-7.69
High:26.54
Open:25.72
Low:25.70
Close:25.34
52wk High:29.80
52wk Low:11.51
Shares:64.96M
Float Shares:33.91M
Volume Ratio:0.58
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4023
EPS(LYR):-2.5724
ROE:-53.76%
ROA:-32.07%
PB:4.70
PE(LYR):-10.17

Loading ...

Pharvaris Is Maintained at Neutral by B of A Securities

Dow Jones
·
Dec 04, 2025

Morgan Stanley Raises Price Target on Pharvaris to $41 From $37, Keeps Overweight Rating

MT Newswires Live
·
Dec 04, 2025

Pharvaris Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 04, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox

Reuters
·
Dec 04, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics

Reuters
·
Dec 03, 2025

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Benzinga_recent_news
·
Dec 03, 2025

Pharvaris Shares Gain 1.2% After Phase 3 Trial Results for Its Hereditary Angioedema Treatment

THOMSON REUTERS
·
Dec 03, 2025

Sector Update: Health Care Stocks Advance Premarket Wednesday

MT Newswires Live
·
Dec 03, 2025

BUZZ-Pharvaris jumps as oral therapy for genetic disorder meets main goal in late-stage trial

Reuters
·
Dec 03, 2025

Pharvaris Shares Jump 19.6% Premarket After Phase 3 Trial Results for Its Hereditary Angioedema Treatment

THOMSON REUTERS
·
Dec 03, 2025

BRIEF-Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study

Reuters
·
Dec 03, 2025

Pharvaris Meets Endpoints in Study of Hereditary Angioedema Treatment

Dow Jones
·
Dec 03, 2025

Pharvaris Announces Positive Phase 3 Results for Deucrictibant in On-Demand HAE Treatment

Reuters
·
Dec 03, 2025

Pharvaris Nv - Deucrictibant Confirmed to Have Well-Tolerated Safety Profile

THOMSON REUTERS
·
Dec 03, 2025

Pharvaris Nv - to Submit Nda to FDA in First Half of 2026

THOMSON REUTERS
·
Dec 03, 2025

Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study Confirming Potential of Deucrictibant for on-Demand Treatment of Hae Attacks

THOMSON REUTERS
·
Dec 03, 2025

Pharvaris Nv - Primary Endpoint Met With Symptom Relief in 1.28 Hours

THOMSON REUTERS
·
Dec 03, 2025

Pharvaris Nv - All Secondary Efficacy Endpoints Met in Rapide-3 Study

THOMSON REUTERS
·
Dec 03, 2025

Pharvaris Reports Q3 2025 Financial Results and Updates

TIPRANKS
·
Nov 27, 2025

Did Analyst Optimism on PHVS Pipeline Outweigh Continued Losses in Pharvaris’ Latest Results?

Simply Wall St.
·
Nov 25, 2025